Similar research findings were observed in lung cancer (LC) and renal cancer patients, where responders to ICI therapy exhibited significantly higher levels of Akkermansia muciniphila (AKK) compared to nonresponders, suggesting that anti‐PD‐1 therapy may induce Th1 immune responses, thereby enhancing cancer immunosurveillance [116]. This evidence concerns the gene PDCD1 and cancer.